HIDRADENITIS SUPPURATIVA (HS)
Clinical trials for HIDRADENITIS SUPPURATIVA (HS) explained in plain language.
Never miss a new study
Get alerted when new HIDRADENITIS SUPPURATIVA (HS) trials appear
Sign up with your email to follow new studies for HIDRADENITIS SUPPURATIVA (HS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug aims to calm painful skin condition
Disease control OngoingThis Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…
Matched conditions: HIDRADENITIS SUPPURATIVA (HS)
Phase: PHASE2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for HS sufferers: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of the drug povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants have already completed 54 weeks of treatment in earlier studies. The goal is to monitor sid…
Matched conditions: HIDRADENITIS SUPPURATIVA (HS)
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Botox study for skin disease pulled before it started
Symptom relief TerminatedThis study aimed to see if Botulinum Toxin-A (Botox) could help people with hidradenitis suppurativa, a painful skin condition. It planned to enroll adults with active armpit lesions of similar severity on both sides. However, the study was withdrawn before any participants were …
Matched conditions: HIDRADENITIS SUPPURATIVA (HS)
Phase: PHASE4 • Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC